trial

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

NCTId NCT00306475
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 60 (actual)
Sponsored by Northwestern University
Primary completion 2008-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-03
Primary completion
2008-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Divalproex Sodium Extended-Release Tablets

Sponsors

Northwestern UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
Abbott Medical DevicesCollaborator

Investigators

1
Stefania Bonaccorso, M.D.Principal Investigator

Sites

1 total
Nashville, United States

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE4
Primary Completion Date
2008-04
Status
COMPLETED
relationships
The graph out of here
drug
Divalproex Sodium Extended-Release Tablets
drug
lead_sponsor
Northwestern University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Abbott Medical Devices
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Stefania Bonaccorso, M.D.
person